S&P 500: 673.80 -1.8% NASDAQ 100: 596.68 -1.9% Dow Jones: 479.22 -2.0%

Jefferies Group’s JAZZ Holdings & Trades

First Buy
Q3 2023
Duration Held
7 Quarters
Largest Add
Q4 2023
+48,001 Shares
Current Position
3,500 Shares
$595,000 Value

Jefferies Group's JAZZ Position Overview

Jefferies Group (via Jefferies Financial Group Inc.) currently holds 3,500 shares of Jazz Pharmaceuticals plc (JAZZ) worth $595,000, representing 0.00% of the portfolio. First purchased in 2023-Q3, this short-term holding has been held for 7 quarters.

Based on 13F filings, Jefferies Group has maintained this position in JAZZ for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2023, adding 48,001 shares. Largest reduction occurred in Q2 2024, reducing 46,662 shares.

Analysis based on 13F filings available since 2013 Q2

Jefferies Group's Jazz Pharmaceuticals plc (JAZZ) Holding Value Over Time

Track share changes against reported price movement

Quarterly Jazz Pharmaceuticals plc (JAZZ) Trades by Jefferies Group

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +3,500 New Buy 3,500 $170.00
Q2 2025 -11,213 Sold Out 0 $0.00
Q1 2025 +11,213 New Buy 11,213 $124.15
Q2 2024 -46,662 Sold Out 0 $0.00
Q1 2024 -3,815 Reduce 7.56% 46,662 $120.42
Q4 2023 +48,001 Add 1938.65% 50,477 $123.00
Q3 2023 +2,476 New Buy 2,476 $129.44

Jefferies Group's Jazz Pharmaceuticals plc Investment FAQs

Jefferies Group first purchased Jazz Pharmaceuticals plc (JAZZ) in Q3 2023, acquiring 2,476 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Jefferies Group has held Jazz Pharmaceuticals plc (JAZZ) for 7 quarters since Q3 2023.

Jefferies Group's largest addition to Jazz Pharmaceuticals plc (JAZZ) was in Q4 2023, adding 50,477 shares worth $6.21 M.

According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 3,500 shares of Jazz Pharmaceuticals plc (JAZZ), valued at approximately $595,000.

As of the Q4 2025 filing, Jazz Pharmaceuticals plc (JAZZ) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.

Jefferies Group's peak holding in Jazz Pharmaceuticals plc (JAZZ) was 50,477 shares, as reported at the end of Q4 2023.